Article

Age, Antipsychotics, and the Risk of Ischemic Stroke in the Veterans Health Administration

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine at Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, USA.
Stroke (Impact Factor: 6.02). 01/2012; 43(1):28-31. DOI: 10.1161/STROKEAHA.111.617191
Source: PubMed

ABSTRACT Time-dependent effects of antipsychotics on risk of stroke and potential effect modification by age have not been fully investigated. A case-case-time-control design uses within- and between-case comparisons to evaluate short-term effects at the same time as adjusting for unmeasured time-invariant confounders and exposure-time trends.
We conducted a case-case-time-control design study using data from the Veterans Health Administration. Veterans with inpatient hospitalizations for ischemic stroke between 2002 and 2007 were included. For every stroke case, the "current" exposure period was defined as 1 to 30 days before hospitalization and the "reference" period as 91 to 120 days before hospitalization. Exposure during the current period was compared with exposure during the reference period within cases. Exposure-time trend-adjusted estimates of the effect of antipsychotic exposure on risk of stroke were obtained by dividing exposure odds for antipsychotic exposure by average exposure odds for other medications over the same time period among the same cases.
After adjusting for exposure-time trends, odds of stroke were 1.8 (95% CI, (1.7-1.9) times higher when exposed to antipsychotics than when unexposed. Age-stratified estimates suggest a greater triggering effect of antipsychotics among older patients.
Exposure to antipsychotics may be a proximal trigger for stroke. Elevation in risk is apparent after brief exposure to antipsychotics.

0 Followers
 · 
104 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objetivo Evaluar la evidencia sobre un incremento de la mortalidad de los pacientes con demencia tratados con antipsicóticos atípicos. Diseño Metaanálisis de los ensayos clínicos publicados en Medline, el registro Cochrane de ensayos clínicos, presentaciones a congresos e información de los promotores de los estudios. La búsqueda bibliográfica se realizó usando los términus aripiprazol, clozapina, olanzapina, quetiapina, risperidona, ziprasidona, demencia, enfermedad de Alzheimer y ensayo clínico. Emplazamiento El metaanálisis se coordinó desde los departamentos de psiquiatría, neurología, geriatría y medicina preventiva de una universidad de Los Ángeles (California, Estados Unidos) y contó con becas de centros de enfermedad de Alzheimer y de la propia universidad. Población de estudio Se incluyeron ensayos clínicos (publicados o no), que fueran aleatorizados y a doble ciego y tuvieran grupos paralelos (antipsicótico atípico oral controlado con placebo), en pacientes con enfermedad de Alzheimer, demencia vascular, mixta o primaria. Los estudios debían informar de las características de los pacientes, la localización, la pauta terapéutica, los abandonos y las muertes. De las 513 referencias bibliográficas (352 de Medline, 118 de Cochrane y 43 de otras fuentes), se revisó detalladamente 94 trabajos, de los que 39 eran ensayos clínicos controlados con placebo y 15 cumplían todos los criterios de inclusión. Factor de estudio Se evaluó la mortalidad (eventos/tiempo de exposición al fármaco) en función del tipo de antipsicótico atípico y del déficit cognitivo basal. De los 15 ensayos clínicos, 3 se realizaron con aripiprazol, 4 con olanzapina, 4 con risperidona, 1 con estos 2 últimos y 3 con quetiapina. El metaanálisis evaluó los resultados de un total de 3.353 pacientes tratados con aripiprazol (603), olanzapina (1.184), risperidona (1.175), quetiapina (391), haloperidol (293) o placebo (1.757). La mayoría incluyó a pacientes ingresados en centros geriátricos (11 de 15). La media de edad fue 81,2 años, el 70% eran mujeres y el 87% tenía diagnóstico de enfermedad de Alzheimer. El déficit cognitivo oscilaba entre moderado y grave, mientras que las medias del test Mini-Mental se situó entre 5,4 y 21,5 según el ensayo clínico. Medición del resultado Mediante el análisis de los resultados de los ensayos clínicos se identificaron los casos de muerte en cada grupo de tratamiento, su incidencia, la odds ratio y el riesgo relativo. También se analizó la heterogeneidad de los resultados de mortalidad en función de los ensayos clínicos y del fármaco. Resultados principales Se identificaron 118 muertes en el grupo con antipsicóticos atípicos y 40 en el grupo con placebo, lo que corresponde a unas incidencias del 3,5 y el 2,3%, respectivamente. La odds ratio general de muerte en pacientes tratados con antipsicóticos atípicos fue de 1,54 (intervalo de confianza [IC] del 95%, 1,06-2,23; p = 0,02). Conclusión Los tratamientos con antipsicóticos atípicos tienen relación con un incremento del riesgo de muerte en pacientes con demencia.
    FMC - Formación Médica Continuada en Atención Primaria 10/2006; 13(8). DOI:10.1016/S1134-2072(06)71377-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent evidence suggests that psychiatric and/or psychological factors could be independent risk factors for stroke. Some of these factors may act as stroke triggers producing short-term physiological changes that may directly lead to stroke onset. Most data is related to four distinct domains: (1) depression and/or anxiety and related syndromes, (2) personality and character traits, (3) psychological stress, and (4) psychotropic medication. Some factors (e.g., depression) are closely related to stroke risk, and there is some evidence that psychological stress could be an important risk factor. However, many studies have methodological limitations (small sample size, lack of adjustment for stroke risk factors, or residual confounding) and lack of standardized definition and/or measurement. Data about stroke triggers is scarce but epidemiological studies suggest a triggering effect of acute or subacute life stress exposure. The potential pathophysiological ways by which psychiatric and/or psychological factors may promote stroke include a higher frequency of unhealthy behaviors and direct biological effects on the cardiovascular system, notably through activation of the sympathetic nervous system. More research is still needed to improve measurement and to better investigate the impact of psychiatric and/or psychological factors. The clarification of pathophysiological mechanisms could help to consider preventive strategies.
    Neuropsychiatric Symptoms of Cerebrovascular Diseases, 01/2013: pages 255-297;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with psychotic disorders have a higher risk of early mortality. In addition to unnatural causes (accidents, suicide), death due to cardiovascular (CV) reasons is two to four times more prevalent in these patients than in the general population. This non-systematic review of MEDLINE aims to clarify the role of all the determining factors are involved. Psychotic disorders are related to unhealthy life habits such as smoking, poor diet and physical inactivity. Neuroleptic drugs have also been studied as triggers of obesity and metabolic syndrome. Therefore, psychotic patients seem predisposed to suffer from several of the «classic» CV risk factors. It is not surprising that their scores on the CV risk scales (Framingham, SCORE) are higher than the general population. We also found publications that showed poorer management of primary and secondary prevention of CV disease. In addition, some biochemical factors (plasma levels of cortisol, ACTH, homocysteine, PCR) may indicate a vulnerability in psychosis per se, as well as the findings on hyperglycemia and insulin resistance in psychotic "drug naive" patients. These "non-classical" factors could alter the validity of CV risk scales designed for the general population. Furthermore, antipsychotic drugs could control intrinsic factors of psychosis (they have shown to reduce global mortality), and their role in CV mortality is not clear.
    Clinica e Investigacion en Arteriosclerosis 07/2013; 26(1). DOI:10.1016/j.arteri.2013.05.006
Show more